FDA Approves MIMRYLO™ (rusfertide), a New Treatment for Adults with Polycythemia Vera
- 7 days ago
- 3 min read
A hepcidin-based approach that could change how erythrocytosis and phlebotomy burden are managed in PV.
The U.S. Food and Drug Administration (FDA) has approved MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), marking an important new development in the therapeutic landscape of myeloproliferative neoplasms (MPN).
The approval, announced on August 28, 2026, makes MIMRYLO the first FDA-approved hepcidin mimetic for polycythemia vera. Rather than working through the mechanisms used by traditional cytoreductive therapies, rusfertide mimics hepcidin, a naturally occurring hormone involved in regulating iron availability.
By limiting the iron available for red blood cell production, the treatment is designed to help reduce erythrocytosis and support hematocrit control.
Why hematocrit control matters in PV
In polycythemia vera, excessive red blood cell production can increase blood viscosity and contribute to an increased risk of thrombotic complications, including blood clots, stroke and other cardiovascular events.
A central treatment goal in PV is therefore to maintain hematocrit below 45%. For many patients, this requires repeated therapeutic phlebotomies, sometimes in addition to treatments such as hydroxyurea, interferon or ruxolitinib.
While phlebotomy can effectively lower hematocrit, the need for repeated procedures can also create a significant burden for some patients and may affect everyday life, symptom management and quality of life.
The VERIFY Phase 3 study
FDA approval was supported by results from the international Phase 3 VERIFY trial, which included 293 adults with PV who remained dependent on phlebotomy despite receiving standard-of-care treatment.
During weeks 20 to 32 of the study, 76.9% of patients receiving rusfertide achieved the defined clinical response compared with 32.9% receiving placebo.
The study also showed:
A reduction in the number of therapeutic phlebotomies.
Improved maintenance of hematocrit below 45%.
Statistically significant improvement in fatigue.
Improvement in overall symptom burden.
From weeks 0 to 32, 62.6% of patients receiving rusfertide maintained hematocrit below 45%, compared with 14.4% in the placebo group. Importantly, the improvement in fatigue, one of the most frequently reported and disruptive symptoms experienced by people living with MPNs, adds a patient-reported outcome dimension to the clinical results.
A different therapeutic approach
MIMRYLO is administered as a once-weekly subcutaneous injection and works by regulating iron availability needed for red blood cell production.
Rather than replacing existing PV therapies, rusfertide offers an additional option to help control erythrocytosis and reduce phlebotomy burden.
The most common adverse reactions reported were injection-site reactions and anemia, with monitoring also recommended for possible increases in platelet counts.
What does this mean globally?
At present, MIMRYLO is FDA-approved in the United States. This approval should therefore not be interpreted as authorization for use in other countries or regions.
Takeda has confirmed that it is working with regulatory authorities outside the United States with the aim of potentially making rusfertide available to patients in additional countries. Further data from the ongoing open-label extension of the VERIFY study are also expected to be presented at future medical meetings.
For the global MPN community, the approval is significant beyond the introduction of a single new medicine. It demonstrates continued progress toward developing treatments that address not only laboratory parameters, but also the treatment burden and lived experience of people with polycythemia vera.
At Global MPN Scientific Foundation, we will continue to follow the clinical development, real-world use and international regulatory progress of rusfertide as further evidence becomes available.
Patients should always discuss treatment decisions with their hematologist or MPN specialist, taking into account their individual disease characteristics, treatment history, symptoms and overall health.
Stay connected with the international community
If you would like to continue learning and connecting with others living with MPN, we invite you to explore the initiatives of Global MPN.
📰 Subscribe to our newsletter to receive updates about research, webinars and community resources.
📝 Register for MPN Journal, a free tool created by patients for patients to track symptoms, treatments and experiences. https://mpn-journal.com
🌿 Explore the Wellbeing Project and discover activities designed to support quality of life. https://www.gmpnsf.org/wellbeing-project
Together, we can help make reliable information more accessible to people living with MPN and their families.
Comments